Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Square Pharmaceuticals's FCF Margin % or its related term are showing as below:
DHA:SQURPHARMA'
s FCF Margin % Range Over the Past 10 Years
Min: 9.36 Med: 16.99 Max: 23.49
Current: 16.74
During the past 13 years, the highest FCF Margin % of Square Pharmaceuticals was 23.49%. The lowest was 9.36%. And the median was 16.99%.
DHA:SQURPHARMA's FCF Margin % is ranked better than 84.23% of 964
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs DHA:SQURPHARMA: 16.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:SQURPHARMA vs ZTS, UTHR: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a FCF Margin % of 4.24% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Square Pharmaceuticals and its competitors. This is 75% below median its historical median of 16.99. Over the past decade, Square Pharmaceuticals' FCF Margin % has ranged from 9.36 to 23.49. According to the industry distribution chart, Square Pharmaceuticals ranks #152 out of 964 companies in the Drug Manufacturers industry, placing it in the top 15.8%.
Is Square Pharmaceuticals' FCF Margin % too high?
Square Pharmaceuticals' current FCF Margin % of 4.24% is 75% below median its 10-year median of 16.99. Over the past 10 years, this metric has ranged from a low of 9.36 to a high of 23.49. The Drug Manufacturers industry median FCF Margin % is 2.74. Square Pharmaceuticals' value of 4.24% is 54.7% above this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #152 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #152 out of 964 companies for FCF Margin %. This places Square Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.74. Square Pharmaceuticals' value of 4.24% is 54.7% above this benchmark. Historically, Square Pharmaceuticals' own FCF Margin % has ranged from 9.36 to 23.49 over the past decade. While the company's 10-year median is 16.99 vs. the industry median of 2.74, Square Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.74, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current FCF Margin % of 4.24% is 54.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current FCF Margin % is 4.24%, which is 75% below median its own 10-year median of 16.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current FCF Margin % is 4.24%, which is 75% below median its 10-year median of 16.99 and 54.7% above the Drug Manufacturers industry median of 2.74. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current FCF Margin % is 4.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
FCF Margin %: 4.24% (75% below median its 10-year median of 16.99)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 54.7% above the Drug Manufacturers median (#152 of 964)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
